Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
12.37
-0.33 (-2.60%)
At close: Apr 24, 2026, 4:00 PM EDT
12.36
-0.01 (-0.12%)
After-hours: Apr 24, 2026, 4:04 PM EDT
Benitec Biopharma Employees
Benitec Biopharma had 19 employees as of June 30, 2025. The number of employees increased by 3 or 18.75% compared to the previous year.
Employees
19
Change (1Y)
3
Growth (1Y)
18.75%
Revenue / Employee
n/a
Profits / Employee
-$2,321,474
Market Cap
423.73M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 19 | 3 | 18.75% |
| Jun 30, 2024 | 16 | -2 | -11.11% |
| Jun 30, 2023 | 18 | 0 | - |
| Jun 30, 2022 | 18 | 4 | 28.57% |
| Jun 30, 2021 | 14 | 0 | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 371 |
| Entrada Therapeutics | 152 |
| Invivyd | 122 |
| Lexeo Therapeutics | 59 |
| Altimmune | 57 |
| PureTech Health | 56 |
| Atea Pharmaceuticals | 55 |
| Eupraxia Pharmaceuticals | 49 |
BNTC News
- 6 weeks ago - Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development for Oculopharyngeal Muscular Dystrophy (OPMD) - GlobeNewsWire
- 3 months ago - Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response - GlobeNewsWire
- 5 months ago - Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update - GlobeNewsWire
- 6 months ago - Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering - GlobeNewsWire
- 6 months ago - Benitec Biopharma Inc. Announces Proposed Public Offering - GlobeNewsWire
- 6 months ago - Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301 - GlobeNewsWire
- 6 months ago - Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy - GlobeNewsWire
- 7 months ago - Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update - GlobeNewsWire